Skip to content

Maclizumab Dexamethasone - a CD163 Targeting Antibody Drug Conjugate directed Macrophages for Treatment of NASH and AAH

The novel ADC inhibits NASH progression in terms of ballooning, fat accumulation and fibrosis

Published: 25th June 2019
Maclizumab Dexamethasone - a CD163 Targeting Antibody Drug Conjugate directed Macrophages for Treatment of NASH and AAH
yodiyim, stock.adobe.com
Patents
  • Intellectual property rights are held by: US9724426B2, CN102686612B and US9476890B2
IP Status
  • Patented
Seeking
  • Development partner
  • Commercial partner
  • Seeking investment